In an adult patient with a history of psychosis, major depressive episode, and bipolar disorder, how long should antipsychotic, antidepressant, and mood‑stabilizing medications be continued after remission?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 8, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Duration of Medication Continuation for Psychosis, Depression, and Bipolar Disorder

Psychosis (First-Episode or Remitted)

Antipsychotic treatment should be continued for at least 12 months after achieving remission of psychotic symptoms. 1

Evidence-Based Duration Guidelines

  • Minimum 12-month continuation is the standard recommendation after remission begins, based on WHO guidelines for psychotic disorders 1
  • Discontinuation before 2 months dramatically increases relapse risk, with maintenance treatment showing significantly fewer relapses at all time points from 2 months onward (RR 0.47-0.55; NNT 3-13) 2
  • At 12 months, maintenance treatment prevents relapse in approximately 53% of patients compared to discontinuation (NNT=3) 2

Long-Term Considerations After Initial 12 Months

  • For patients stable for several years, withdrawal may be considered only with close monitoring, understanding that relapse risk increases substantially 1
  • Approximately 45.7% of first-episode patients who discontinued antipsychotics at 12 months did not relapse, suggesting some patients may successfully discontinue 2
  • However, twice as many relapses occur with discontinuation strategies (43% vs. 21%) in first-episode psychosis 3

Critical Factors Predicting Higher Relapse Risk

  • Diagnosis of schizophrenia (versus other psychotic disorders) 4
  • Longer duration of untreated illness 4
  • Poor premorbid functioning 4
  • Multiple prior episodes 1

Discontinuation Strategy (If Pursued After 12+ Months)

  • Must involve gradual tapering over several months (mean 3 months in studies), never abrupt discontinuation 2
  • Requires intensive monitoring with specialized first-episode psychosis services 4
  • Should be supervised by mental health professionals with family consultation 1
  • Only feasible in approximately 20% of first-episode patients 3

Major Depressive Disorder (Unipolar Depression)

Antidepressant treatment should continue for 4 to 12 months after a first episode of major depression achieves remission. 1

Duration Based on Episode History

  • First episode: 4-12 months of continuation treatment after remission 1
  • Second episode (50% recurrence risk): Consider extending treatment beyond 12 months 1
  • Third or more episodes (90% recurrence risk): Prolonged or indefinite treatment is warranted 1

Evidence for Extended Treatment

  • Systematic reviews demonstrate that continued antidepressant treatment after remission protects against recurrence and relapse 1
  • A randomized trial showed significantly lower recurrence rates with maintenance venlafaxine or fluoxetine compared to placebo after both 12-month and 24-month follow-up periods 1
  • Discontinuing antidepressants at the end of the acute phase (before 4 months) does not prevent relapse 1

Real-World Practice Patterns

  • More than 60% of Americans on antidepressants continue treatment longer than 2 years 1
  • 14% continue for 10 years or longer 1

Bipolar Disorder

Maintenance treatment with mood stabilizers (lithium or valproate) should continue for at least 2 years after the last mood episode. 1

Minimum Duration Requirements

  • At least 2 years of maintenance therapy after the last episode of mania, depression, or mixed state 1
  • Decision to continue beyond 2 years should preferably involve a mental health specialist 1

Evidence Supporting Extended Treatment

  • Withdrawal of maintenance lithium therapy dramatically increases relapse risk, especially within the first 6 months after discontinuation 1
  • More than 90% of adolescents who were noncompliant with lithium relapsed, compared to 37.5% of compliant patients 5
  • Maintenance therapy continuing for at least 12-24 months after mood stabilization is recommended by multiple guidelines 5

Antipsychotic Duration in Bipolar Disorder

  • When antipsychotics are used for acute mania, they should be continued for at least 12 months after remission begins 1
  • For patients stable on antipsychotics for several years, withdrawal may be considered with careful monitoring and specialist consultation 1

Antidepressant Duration in Bipolar Depression

  • Antidepressants in bipolar disorder must always be combined with a mood stabilizer (lithium or valproate) 1
  • SSRIs (fluoxetine preferred) should be used over tricyclic antidepressants 1
  • Duration should follow the same 2-year minimum as mood stabilizers, with ongoing reassessment 1

Special Considerations for Indefinite Treatment

  • Some individuals will require lifelong treatment when benefits outweigh risks 1, 5
  • Factors favoring indefinite treatment include:
    • Multiple severe episodes 5
    • Rapid cycling patterns 5
    • History of serious suicide attempts 5
    • Poor response to alternative agents 5

Common Pitfalls to Avoid Across All Conditions

  • Premature discontinuation is the most common error, leading to relapse rates exceeding 90% in some populations 1, 5
  • Abrupt cessation rather than gradual tapering increases rebound symptoms and relapse risk 2
  • Inadequate monitoring during and after discontinuation attempts 1
  • Failing to involve family/caregivers in discontinuation decisions 1
  • Discontinuing during high-stress periods or without adequate psychosocial support 1

Monitoring During Continuation/Maintenance

  • Monthly follow-up for the first 6-12 months after achieving remission 5
  • Close monitoring for 2-3 months after any medication discontinuation, as this is the highest-risk period for relapse 5
  • Assessment at every visit should include: ongoing symptoms, suicide risk, adverse effects, medication adherence, and environmental stressors 5

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.